Vernon G. Wong, MD, FACS, is the founder of Icon Bioscience, Inc. Dr. Wong is a pioneer in the field of drug delivery dating back to the early 1970’s. Dr. Wong was the first clinical director of the National Eye Institute and was a tenured Professor at Georgetown University Medical School. He has published over 100 scientific papers. He co-founded and was the core patent holder in Oculex Pharmaceuticals, which was acquired by Allergan Pharmaceuticals for $245 million in 2002.
Chief Executive Officer
David S. Tierney, M.D./Signet Healthcare Partners
Dr. David Tierney is a Venture Partner with Signet Healthcare Partners, a NYC based life sciences private equity fund. Prior to joining Signet, David was a Co-founder, President and COO of Oceana Therapeutics, a specialty medical device company focused on urologic and GI disorders. Oceana was acquired by Salix Pharmaceuticals, Inc. in December 2011. From 2000 to 2007, David was President, CEO and Director for Valera Pharmaceuticals.
Under David’s leadership, Valera actively pursued and received a number of regulatory product approvals and successfully completed an initial public offering in 2006. Shortly thereafter, Valera was acquired in 2007 by Endo Pharmaceuticals. Prior to Valera, David served as President of Biovail Technologies (a division of Biovail Corp.), and from 1997 through 1999, he held the position of Senior Vice President, Drug Development, for Roberts Pharmaceutical Corp. Before joining Roberts, David spent eight years at Elan Corp. in a variety of management positions. David also serves on the Board of Directors of Catalyst Pharmaceutical Partners (CPRX:NASDAQ) and Bioject, Inc.
A recipient of 2005 and 2011 Ernst & Young Entrepreneur Of The Year® Awards, David was named to the 2005, 2006 and 2011 PharmaVOICE lists of the 100 Most Inspiring People in the Life Sciences Industry. He was also featured in the 2010 inaugural Irish Life Science 50, an honor bestowed by the Irish Voice newspaper and Irish America magazine in conjunction with the Irish Government. David received his medical degree from the Royal College of Surgeons in Dublin, Ireland.
Vice President, Clinical Development
Wendy Yee Murahashi, MD joined IBI in October, 2011 and is responsible for all regulatory and clinical activities. She is an American Academy of Ophthalmology board-certified ophthalmologist with subspecialty training in retina and vitreous. She previously served as Clinical Instructor at the Portland VA Hospital/Casey Eye Institute. Prior to joining IBI, Dr. Murahashi was a Medical Director at Genentech/Roche with clinical trial responsibility involving the Lucentis® program.
Vice President, Finance
Mr. Hector Casab joined Icon Bioscience in January 2014 and is responsible for all finance and accounting activities. Prior to joining IBI, Mr. Casab was head of Financial Planning at Onyx Pharmaceuticals, supporting the company’s operational and financial growth of multiple product launches in oncology. He previously held roles in finance and operations at Genentech and Applied Biosystems. Mr. Casab earned his MBA from Santa Clara University.
Mr. David Williams has over 25 years of experience in cGMP large and small molecule manufacturing operations, process development/ scale-up, facility design and construction, state and local incentive development programs, and R&D. Prior to TS consulting, he was Senior Vice President of Operations for Chlorogen, Inc., in St. Louis, MO. He joined Chlorogen in June 2003 from CropTech Corporation in Blacksburg, Virginia, where he served as Chief Technology Officer and Sr. VP of Operations. Mr. Williams also served with Monsanto Company as Vice President of Operations for the Integrated Protein Technologies (IPT) business unit; Cephalon, Inc., as Director of Operations; founding partner and VP of Operations for Bio Science Contract Production Corporation (which became Cambrex Bio Science); and North American Vaccine as Director of Manufacturing for pediatric vaccines. Mr. Williams holds a M.S. degree in industrial Microbiology/Biochemistry, and completed PhD. requirements, all but dissertation, in Microbiology/Biochemistry from the University of Oklahoma.